Zhejiang Ausun Pharmaceutical Co Ltd (603229) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Ausun Pharmaceutical Co Ltd (603229) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥121.49 Million ≈ $17.78 Million USD) by net assets (CN¥2.35 Billion ≈ $343.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zhejiang Ausun Pharmaceutical Co Ltd (603229) balance sheet quality index to measure how much of total assets are equity-financed.
Zhejiang Ausun Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Zhejiang Ausun Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Zhejiang Ausun Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Zhejiang Ausun Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Ausun Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Episil-Precision Inc
TW:3016
|
0.019x |
|
PATTIES FOODS
F:PH4
|
N/A |
|
Centerspace
NYSE:CSR
|
0.026x |
|
Vitec Software Group AB (publ)
ST:VIT-B
|
0.155x |
|
AMG Advanced Metallurgical Group NV
AS:AMG
|
-0.018x |
|
SY HOLDINGS GROUP HD-01
F:9U0
|
N/A |
|
Medartis Holding AG
SW:MED
|
0.088x |
|
Tianjin Silvery Dragon
SHG:603969
|
0.026x |
Annual Cash Flow Conversion Efficiency for Zhejiang Ausun Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Zhejiang Ausun Pharmaceutical Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.27 Billion ≈ $332.08 Million |
CN¥156.51 Million ≈ $22.90 Million |
0.069x | -11.94% |
| 2024-12-31 | CN¥2.27 Billion ≈ $332.45 Million |
CN¥177.93 Million ≈ $26.04 Million |
0.078x | -24.40% |
| 2023-12-31 | CN¥2.14 Billion ≈ $313.38 Million |
CN¥221.85 Million ≈ $32.46 Million |
0.104x | +25.54% |
| 2022-12-31 | CN¥1.46 Billion ≈ $213.81 Million |
CN¥120.57 Million ≈ $17.64 Million |
0.083x | -40.46% |
| 2021-12-31 | CN¥1.25 Billion ≈ $183.62 Million |
CN¥173.90 Million ≈ $25.45 Million |
0.139x | +12.78% |
| 2020-12-31 | CN¥1.13 Billion ≈ $164.90 Million |
CN¥138.47 Million ≈ $20.26 Million |
0.123x | -9.63% |
| 2019-12-31 | CN¥645.19 Million ≈ $94.41 Million |
CN¥87.73 Million ≈ $12.84 Million |
0.136x | +606.38% |
| 2018-12-31 | CN¥597.60 Million ≈ $87.45 Million |
CN¥11.50 Million ≈ $1.68 Million |
0.019x | -76.76% |
| 2017-12-31 | CN¥564.93 Million ≈ $82.67 Million |
CN¥46.78 Million ≈ $6.85 Million |
0.083x | -78.38% |
| 2016-12-31 | CN¥243.30 Million ≈ $35.60 Million |
CN¥93.21 Million ≈ $13.64 Million |
0.383x | +34.36% |
| 2015-12-31 | CN¥188.07 Million ≈ $27.52 Million |
CN¥53.63 Million ≈ $7.85 Million |
0.285x | +3.96% |
| 2014-12-31 | CN¥78.21 Million ≈ $11.44 Million |
CN¥21.45 Million ≈ $3.14 Million |
0.274x | -42.62% |
| 2013-12-31 | CN¥32.91 Million ≈ $4.82 Million |
CN¥15.73 Million ≈ $2.30 Million |
0.478x | +534.85% |
| 2012-12-31 | CN¥10.36 Million ≈ $1.52 Million |
CN¥-1.14 Million ≈ $-166.57K |
-0.110x | -- |
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more